Navidea Biopharma (NAVB) Reports Q4 Loss of $0.03

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.03), versus ($0.02) reported last year. Revenue for the quarter came in at $395 thousand, versus $1 million reported last year.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Goldman Sachs reports global fund inflows for week of July 8
• Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season